Tags : IMC-C103C

Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated

Shots: Immunocore to receive $100M upfront plus milestone payment and has an option to license IMC-C103C or grant its full rights to Genentech. If not exercised option to license, Immunocore will receive milestones and royalties Immunocore will conduct clinical trial to evaluate IMC-C103C as a monothx or in combination with Tecentriq (atezolizumab), which will be […]Read More